首页 / 产品 / 抗体 / 一抗

Rabbit Monoclonal CTRL Antibody

  • 中文名： CTRL抗体
  • 别    名： CTRL; CTRL1;;CTRL
货号: IPDX18048
Price： ￥1280
数量：
大包装询价

验证与应用

应用及物种
WB 咨询技术 Human,Mouse,Rat
IF 咨询技术 Human,Mouse,Rat
IHC 咨询技术 Human,Mouse,Rat
ICC 技术咨询 Human,Mouse,Rat
FCM 咨询技术 Human,Mouse,Rat
Elisa 咨询技术 Human,Mouse,Rat

产品详情

AliasesCTRL; CTRL1;;CTRL
WB Predicted band sizeCalculated MW: 28 kDa ; Observed MW: 24,28 kDa
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman,Mouse,Rat
ImmunogenA synthesized peptide derived from human CTRL
FormulationPurified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol.

+ +

参考文献

以下是关于CTRL(Cholecystokinin Receptor-Like)抗体的参考文献示例(内容为模拟生成，建议通过学术数据库核实最新研究)：

---

1. **文献名称**: *"Development and Characterization of a High-Affinity CTRL Antibody for Pancreatic Cancer Imaging"*

**作者**: Zhang Y, et al.

**摘要**: 本研究开发了一种针对CTRL蛋白的高特异性单克隆抗体，并验证其在胰腺癌组织中的高表达。该抗体通过免疫组化和活体成像技术证实了其靶向性，为肿瘤诊断提供了潜在工具。

2. **文献名称**: *"CTRL Antibody as a Novel Biomarker in Autoimmune Cholangiopathy"*

**作者**: Müller S, et al.

**摘要**: 文章发现CTRL抗体在原发性胆汁性胆管炎(PBC)患者血清中显著升高，提示其可能作为疾病活动的生物标志物，并探讨了其与胆管细胞凋亡的关联机制。

3. **文献名称**: *"Targeting CTRL in Neuroendocrine Tumors: A Therapeutic Antibody Study"*

**作者**: Gupta R, et al.

**摘要**: 研究报道了一种人源化抗CTRL抗体，可通过阻断受体信号通路抑制神经内分泌肿瘤细胞的增殖，动物实验显示其显著缩小肿瘤体积并延长生存期。

4. **文献名称**: *"Cross-Reactivity Analysis of Commercial CTRL Antibodies: Implications for Research Reproducibility"*

**作者**: Lee JH, et al.

**摘要**: 通过对比6种市售CTRL抗体的特异性，发现部分抗体存在与非靶蛋白的交叉反应，强调了抗体验证在实验可重复性中的重要性。

---

建议通过PubMed或Web of Science以“CTRL antibody”或“Cholecystokinin receptor antibody”为关键词检索最新文献，获取领域内权威研究。

背景信息

The CTRL antibody, often associated with immune regulation, targets specific molecules involved in modulating immune responses. While "CTRL" isn't a standard abbreviation in mainstream immunology, it may refer to antibodies designed to control or inhibit specific pathways, such as immune checkpoints. For instance, antibodies like anti-CTLA-4 (e.g., ipilimumab) or anti-PD-1/PD-L1 function as "control" agents in cancer immunotherapy by blocking inhibitory signals, thereby reactivating T-cell-mediated tumor destruction. Alternatively, CTRL antibodies might serve as experimental tools to study regulatory mechanisms in autoimmune diseases or inflammation. In therapeutic contexts, such antibodies are engineered to bind precise epitopes on target proteins, altering signaling cascades or cellular interactions. Their development often involves hybridoma technology or recombinant methods to ensure specificity and affinity. Research on CTRL-like antibodies has expanded into treating conditions like melanoma, rheumatoid arthritis, and multiple sclerosis, reflecting their dual role in both suppressing harmful immune activity and enhancing protective responses. Ongoing studies focus on minimizing off-target effects and optimizing pharmacokinetics to improve clinical outcomes.

客户数据及评论

折叠内容

大包装询价

×